Ionis Pharmaceuticals (IONS) Stock: Charts & Financials

Ionis Pharmaceuticals, Inc.(IONS)

Biotechnology · Carlsbad, CA

$44.00+0.50 (+1.15%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Ionis Pharmaceuticals, Inc.

Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.

Carlsbad, CA

1,480 employees

www.ionis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Brett Monia

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	873.76M	267.95M	246.09M	203.00M	156.72M	452.05M	131.61M	226.58M	133.81M
Cost of Goods Sold	16.06M	2.74M	2.98M	8.00M	2.34M	4.15M	1.50M	3.83M	1.07M
Gross Profit	857.70M	265.21M	243.11M	195.00M	154.38M	447.90M	130.11M	222.75M	132.74M
Gross Profit Margin	98.2%	99.0%	98.8%	96.1%	98.5%	99.1%	98.9%	98.3%	99.2%
Total Operating Expenses	1.45B	367.50M	360.53M	410.00M	314.56M	308.08M	276.97M	333.57M	281.40M
Research & Development	925.03M	217.11M	210.17M	280.00M	217.75M	217.46M	200.76M	245.49M	219.76M
Selling, General & Administrative	527.55M	150.40M	150.36M	130.00M	96.80M	90.60M	76.30M	88.10M	61.60M
Operating Income (EBIT)	-594.90M	-102.29M	-117.42M	-215.00M	-160.18M	139.82M	-146.86M	-110.82M	-148.66M
Operating Margin	-68.1%	-38.2%	-47.7%	-105.9%	-102.2%	30.9%	-111.6%	-48.9%	-111.1%
Income Before Tax (EBT)	-562.09M	-113.38M	-92.31M	-228.00M	-128.39M	123.53M	-146.82M	-107.04M	-144.10M
Interest Income	94.13M	20.23M	25.48M	24.73M	23.68M	24.69M	24.67M	28.91M	26.23M
Interest Expense	89.47M	22.12M	22.50M	22.69M	22.16M	22.76M	22.93M	22.86M	22.69M
Other Income/Expense	32.81M	-11.09M	25.11M	-13.00M	31.79M	-16.29M	38K	3.78M	4.55M
Net Income	-564.78M	-114.65M	-92.53M	-229.00M	-128.61M	123.55M	-146.94M	-104.35M	-140.48M
Income Tax Expense	167K	-1.26M	218K	1.00M	213K	-20K	116K	-2.69M	-3.62M
Net Profit Margin	-64.6%	-42.8%	-37.6%	-112.8%	-82.1%	27.3%	-111.6%	-46.1%	-105.0%
EBITDA	4.24B	-98.86M	-110.64M	4.60B	-155.68M	145.27M	-141.46M	-105.56M	-143.16M
EBITDA Margin	485.0%	-36.9%	-45.0%	2267.2%	-99.3%	32.1%	-107.5%	-46.6%	-107.0%
Depreciation & Amortization	4.83B	3.43M	6.79M	4.82B	4.50M	5.45M	5.40M	5.27M	5.49M
EPS Basic	-3.46	-0.69	-0.56	-1.41	-0.80	0.78	-0.93	-0.66	-0.95
EPS Diluted	-3.46	-0.69	-0.56	-1.41	-0.80	0.68	-0.93	-0.66	-0.95
Weighted Average Basic Shares	165.42M	165.42M	164.87M	162.00M	160.76M	159.14M	158.74M	158.00M	148.59M
Weighted Average Diluted Shares	165.42M	165.42M	164.87M	162.00M	160.76M	182.33M	158.74M	158.00M	148.59M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

873.76M

267.95M

246.09M

203.00M

156.72M

452.05M

131.61M

226.58M

133.81M

Cost of Goods Sold

16.06M

2.74M

2.98M

8.00M

2.34M

4.15M

1.50M

3.83M

1.07M

Gross Profit

857.70M

265.21M

243.11M

195.00M

154.38M

447.90M

130.11M

222.75M

132.74M

Gross Profit Margin

98.2%

99.0%

98.8%

96.1%

98.5%

99.1%

98.9%

98.3%

99.2%

Total Operating Expenses

1.45B

367.50M

360.53M

410.00M

314.56M

308.08M

276.97M

333.57M

281.40M

Research & Development

925.03M

217.11M

210.17M

280.00M

217.75M

217.46M

200.76M

245.49M

219.76M

Selling, General & Administrative

527.55M

150.40M

150.36M

130.00M

96.80M

90.60M

76.30M

88.10M

61.60M

Operating Income (EBIT)

-594.90M

-102.29M

-117.42M

-215.00M

-160.18M

139.82M

-146.86M

-110.82M

-148.66M

Operating Margin

-68.1%

-38.2%

-47.7%

-105.9%

-102.2%

30.9%

-111.6%

-48.9%

-111.1%

Income Before Tax (EBT)

-562.09M

-113.38M

-92.31M

-228.00M

-128.39M

123.53M

-146.82M

-107.04M

-144.10M

Interest Income

94.13M

20.23M

25.48M

24.73M

23.68M

24.69M

24.67M

28.91M

26.23M

Interest Expense

89.47M

22.12M

22.50M

22.69M

22.16M

22.76M

22.93M

22.86M

22.69M

Other Income/Expense

32.81M

-11.09M

25.11M

-13.00M

31.79M

-16.29M

38K

3.78M

4.55M

Net Income

-564.78M

-114.65M

-92.53M

-229.00M

-128.61M

123.55M

-146.94M

-104.35M

-140.48M

Income Tax Expense

167K

-1.26M

218K

1.00M

213K

-20K

116K

-2.69M

-3.62M

Net Profit Margin

-64.6%

-42.8%

-37.6%

-112.8%

-82.1%

27.3%

-111.6%

-46.1%

-105.0%

EBITDA

4.24B

-98.86M

-110.64M

4.60B

-155.68M

145.27M

-141.46M

-105.56M

-143.16M

EBITDA Margin

485.0%

-36.9%

-45.0%

2267.2%

-99.3%

32.1%

-107.5%

-46.6%

-107.0%

Depreciation & Amortization

4.83B

3.43M

6.79M

4.82B

4.50M

5.45M

5.40M

5.27M

5.49M

EPS Basic

-3.46

-0.69

-0.56

-1.41

-0.80

0.78

-0.93

-0.66

-0.95

EPS Diluted

-3.46

-0.69

-0.56

-1.41

-0.80

0.68

-0.93

-0.66

-0.95

Weighted Average Basic Shares

165.42M

164.87M

162.00M

160.76M

159.14M

158.74M

158.00M

148.59M

Weighted Average Diluted Shares

165.42M

164.87M

162.00M

160.76M

182.33M

158.74M

158.00M

148.59M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	944.00M	705.14M	787.65M	587.37M	810.46M	729.26M	1.12B	599.67M
Cost of Goods Sold	16.00M	11.21M	9.13M	14.12M	10.84M	11.95M	4.38M	1.82M
Gross Profit	928.00M	693.92M	778.51M	573.25M	799.61M	717.32M	1.12B	597.85M
Gross Profit Margin	98.3%	98.4%	98.8%	97.6%	98.7%	98.4%	99.6%	99.7%
Total Operating Expenses	1.31B	1.17B	1.13B	983.44M	829.80M	889.40M	752.33M	659.23M
Research & Development	916.00M	901.53M	899.63M	833.00M	643.00M	535.00M	466.00M	414.60M
Selling, General & Administrative	394.00M	267.50M	232.60M	150.29M	170.90M	332.20M	286.64M	244.62M
Operating Income (EBIT)	-382.00M	-475.08M	-353.73M	-410.19M	-30.19M	-172.08M	365.88M	-61.37M
Operating Margin	-40.5%	-67.4%	-44.9%	-69.8%	-3.7%	-23.6%	32.6%	-10.2%
Income Before Tax (EBT)	-380.00M	-460.07M	-333.96M	-257.99M	-29.15M	-134.55M	338.77M	-76.16M
Interest Income	97.77M	107.02M	89.04M	25.33M	10.04M	30.56M	52.20M	30.19M
Interest Expense	90.54M	90.45M	81.46M	8.12M	9.35M	9.51M	48.77M	44.79M
Other Income/Expense	2.00M	15.01M	19.77M	152.21M	1.04M	37.53M	-27.12M	-14.78M
Net Income	-381.00M	-453.90M	-366.29M	-269.72M	-28.60M	-444.26M	278.14M	273.74M
Income Tax Expense	1.00M	-6.17M	32.32M	11.74M	-551K	345.19M	51.51M	-291.14M
Net Profit Margin	-40.4%	-64.4%	-46.5%	-45.9%	-3.5%	-60.9%	24.8%	45.6%
EBITDA	-361.75M	-453.09M	-331.23M	-388.09M	-10.63M	-154.92M	381.88M	-48.84M
EBITDA Margin	-38.3%	-64.3%	-42.1%	-66.1%	-1.3%	-21.2%	34.0%	-8.1%
Depreciation & Amortization	20.25M	21.99M	22.50M	22.11M	19.56M	17.16M	15.99M	12.53M
EPS Basic	-2.38	-3.04	-2.56	-1.90	-0.20	-3.18	2.10	2.07
EPS Diluted	-2.38	-3.04	-2.56	-1.90	-0.20	-3.18	2.06	2.04
Weighted Average Basic Shares	160.00M	149.51M	143.00M	141.85M	141.02M	139.61M	140.00M	132.32M
Weighted Average Diluted Shares	160.00M	149.51M	143.19M	141.85M	141.02M	139.61M	142.87M	134.06M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

944.00M

705.14M

787.65M

587.37M

810.46M

729.26M

1.12B

599.67M

Cost of Goods Sold

16.00M

11.21M

9.13M

14.12M

10.84M

11.95M

4.38M

1.82M

Gross Profit

928.00M

693.92M

778.51M

573.25M

799.61M

717.32M

1.12B

597.85M

Gross Profit Margin

98.3%

98.4%

98.8%

97.6%

98.7%

98.4%

99.6%

99.7%

Total Operating Expenses

1.31B

1.17B

1.13B

983.44M

829.80M

889.40M

752.33M

659.23M

Research & Development

916.00M

901.53M

899.63M

833.00M

643.00M

535.00M

466.00M

414.60M

Selling, General & Administrative

394.00M

267.50M

232.60M

150.29M

170.90M

332.20M

286.64M

244.62M

Operating Income (EBIT)

-382.00M

-475.08M

-353.73M

-410.19M

-30.19M

-172.08M

365.88M

-61.37M

Operating Margin

-40.5%

-67.4%

-44.9%

-69.8%

-3.7%

-23.6%

32.6%

-10.2%

Income Before Tax (EBT)

-380.00M

-460.07M

-333.96M

-257.99M

-29.15M

-134.55M

338.77M

-76.16M

Interest Income

97.77M

107.02M

89.04M

25.33M

10.04M

30.56M

52.20M

30.19M

Interest Expense

90.54M

90.45M

81.46M

8.12M

9.35M

9.51M

48.77M

44.79M

Other Income/Expense

2.00M

15.01M

19.77M

152.21M

1.04M

37.53M

-27.12M

-14.78M

Net Income

-381.00M

-453.90M

-366.29M

-269.72M

-28.60M

-444.26M

278.14M

273.74M

Income Tax Expense

1.00M

-6.17M

32.32M

11.74M

-551K

345.19M

51.51M

-291.14M

Net Profit Margin

-40.4%

-64.4%

-46.5%

-45.9%

-3.5%

-60.9%

24.8%

45.6%

EBITDA

-361.75M

-453.09M

-331.23M

-388.09M

-10.63M

-154.92M

381.88M

-48.84M

EBITDA Margin

-38.3%

-64.3%

-42.1%

-66.1%

-1.3%

-21.2%

34.0%

-8.1%

Depreciation & Amortization

20.25M

21.99M

22.50M

22.11M

19.56M

17.16M

15.99M

12.53M

EPS Basic

-2.38

-3.04

-2.56

-1.90

-0.20

-3.18

2.10

2.07

EPS Diluted

-2.38

-3.04

-2.56

-1.90

-0.20

-3.18

2.06

2.04

Weighted Average Basic Shares

160.00M

149.51M

143.00M

141.85M

141.02M

139.61M

140.00M

132.32M

Weighted Average Diluted Shares

160.00M

149.51M

143.19M

141.85M

141.02M

139.61M

142.87M

134.06M

Income Statement

Quarterly Income Statement (USD)

Annual Income Statement (USD)